[{"id":"23758911-8745-4e04-b970-f675198d8588","acronym":"PRINCESS","url":"https://clinicaltrials.gov/study/NCT05821751","created_at":"2023-04-20T14:03:53.992Z","updated_at":"2024-07-02T16:35:50.012Z","phase":"","brief_title":"The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT05821751 - PRINCESS","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 12/02/2024","primary_completion_date":" 12/02/2024","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2023-04-20"},{"id":"398611ec-32d5-4767-9ab0-d167a02f0c96","acronym":"ICE","url":"https://clinicaltrials.gov/study/NCT05727813","created_at":"2023-02-14T18:02:36.078Z","updated_at":"2024-07-02T16:35:55.606Z","phase":"","brief_title":"To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)","source_id_and_acronym":"NCT05727813 - ICE","lead_sponsor":"University of Roma La Sapienza","biomarkers":" IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/16/2023","primary_completion_date":" 01/16/2023","study_txt":" Completion: 01/27/2023","study_completion_date":" 01/27/2023","last_update_posted":"2023-02-14"},{"id":"b61b36ed-ff52-451e-a650-5e97ce622140","acronym":"NL77292.056.21","url":"https://clinicaltrials.gov/study/NCT05303480","created_at":"2022-03-31T18:53:01.830Z","updated_at":"2024-07-02T16:35:57.111Z","phase":"","brief_title":"Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides","source_id_and_acronym":"NCT05303480 - NL77292.056.21","lead_sponsor":"Centre for Human Drug Research, Netherlands","biomarkers":" PD-L1 • CD8 • CXCL8 • CD4 • CCL20 • IL1A • CCL27 • IL13 • IL1R1 • IL4","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • CXCL8 • CD4 • CCL20 • IL1A • CCL27 • IL13 • IL1R1 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Valchlor (mechlorethamine gel)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/08/2022","primary_completion_date":" 12/08/2022","study_txt":" Completion: 12/08/2022","study_completion_date":" 12/08/2022","last_update_posted":"2023-01-24"},{"id":"024e1277-d133-4914-a627-57cfe108a970","acronym":"TruCulture","url":"https://clinicaltrials.gov/study/NCT04127864","created_at":"2021-01-18T20:09:51.316Z","updated_at":"2024-07-02T16:36:05.964Z","phase":"","brief_title":"Perioperative Immune Function in Patients Undergoing Colorectal Cancer Surgery","source_id_and_acronym":"NCT04127864 - TruCulture","lead_sponsor":"University of Copenhagen","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/14/2019","start_date":" 10/14/2019","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-08-05"},{"id":"66e0fc5a-b053-47ce-b084-660c0c6c06be","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696056","created_at":"2021-01-18T18:06:55.792Z","updated_at":"2024-07-02T16:36:38.964Z","phase":"","brief_title":"Improving Brain Function After Breast Cancer Study","source_id_and_acronym":"NCT03696056","lead_sponsor":"University of Texas at Austin","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL13 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL13 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/30/2020","study_completion_date":" 01/30/2020","last_update_posted":"2020-11-09"},{"id":"333965c4-6c89-43f0-ad5b-8e2544276d05","acronym":"","url":"https://clinicaltrials.gov/study/NCT03331367","created_at":"2021-01-18T16:27:04.596Z","updated_at":"2024-07-02T16:36:42.214Z","phase":"","brief_title":"Investigating and Characterizing the Immune Response to Prostate Cancer","source_id_and_acronym":"NCT03331367","lead_sponsor":"NYU Langone Health","biomarkers":" IFNG • IL6 • TNFA • CXCL8 • IL2RA • IL2 • IL10 • IL13 • IL1B • IL4 • IL5 • ISG20","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • CXCL8 • IL2RA • IL2 • IL10 • IL13 • IL1B • IL4 • IL5 • ISG20"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/14/2017","start_date":" 09/14/2017","primary_txt":" Primary completion: 02/25/2020","primary_completion_date":" 02/25/2020","study_txt":" Completion: 02/25/2020","study_completion_date":" 02/25/2020","last_update_posted":"2020-08-07"},{"id":"e90d90e5-33e6-4be3-bd2c-8d8dccd30023","acronym":"","url":"https://clinicaltrials.gov/study/NCT04355806","created_at":"2021-01-18T21:03:23.571Z","updated_at":"2024-07-02T16:36:45.824Z","phase":"","brief_title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","source_id_and_acronym":"NCT04355806","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2020-04-21"},{"id":"946167b1-ae30-4193-b3c5-e6cd59faf01a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00730613","created_at":"2021-01-18T02:45:06.814Z","updated_at":"2024-07-02T16:37:17.237Z","phase":"Phase 1","brief_title":"Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma","source_id_and_acronym":"NCT00730613","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL13","pipe":"","alterations":" ","tags":["IL13"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 02/01/2002","start_date":" 02/01/2002","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":" Completion: 08/01/2011","study_completion_date":" 08/01/2011","last_update_posted":"2017-10-09"},{"id":"c7cb12bd-00a5-4666-8ffc-015f0ac907fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03093623","created_at":"2021-01-18T15:14:29.764Z","updated_at":"2024-07-02T16:37:23.535Z","phase":"","brief_title":"The Effect of Physical Activity and Abstain From Smoking on the Precancerous Lesion","source_id_and_acronym":"NCT03093623","lead_sponsor":"Taipei Medical University","biomarkers":" IL2 • IL10 • TNFRSF1A • IL13 • IL4 • IL5","pipe":"","alterations":" ","tags":["IL2 • IL10 • TNFRSF1A • IL13 • IL4 • IL5"],"overall_status":"Unknown status","enrollment":" Enrollment 446","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-04-11"}]